Considering CD47 levels were decreased to background levels with the use of NDV-αCD47, NDV-SIRPα-Fc, and NDV in combination with recombinant anti-CD47 given independently, it is unlikely that this lack of synergy is attributed to the quantity of anti-CD47 or SIRPα-Fc produced or on-target, off-tumor specificity.47 Here, SIRPA is linked to neoplasm.